BLACK WEEKSFrascos −15% · kits −10% · resto −5%com o códigoEnvio grátis na Alemanha a partir de 200 €

Esta página foi traduzida automaticamente e pode conter erros. É falante nativo? Agradecemos o seu feedback e as suas correções.Enviar feedback

The Peptide Desk The Peptide Desk
Tamoxifen (Nolvadex), foto do produto

Relatório laboratorial

PDF
Testado
Testado
Tamoxifen (Nolvadex) 20mg × 100 Tabs
Laboratório
Analiza Białek
Data
October 2026
Resultado
20.34 mg per tablet (20 mg label)
N.º da encomenda
Palavra-passe

Testado de forma independente, verificável com a palavra-passe diretamente no laboratório.

PCT & AI

Tamoxifen (Nolvadex)

PCT & AI

Encomenda

Preço unitário - Envio grátis na Alemanha a partir de 200 € durante as Black Weeks
  • DHL com seguimento
  • Embalagem discreta

4.6 de 5 no Trustpilot73 avaliações

Num relance

Tamoxifen (Nolvadex) em números

Os valores-chave da nossa enciclopédia.

Entrada completa da enciclopédia
Class
SERMestrogen receptor modulator
Half-life
longseveral days
Use
Oraldaily
Sizes
10 to 20 mg2 sizes in the shop

Conhecimento

Tudo sobre Tamoxifen (Nolvadex)

FAQ

Perguntas frequentes

Fontes de cada resposta: entrada da enciclopédia

Ainda tem alguma pergunta?

Escreva-nos, a nossa equipa ajuda.

Is tamoxifen approved?

Yes. ChEMBL lists tamoxifen with phase 4 as the highest phase and first approval in 1977. ClinicalTrials.gov lists 685 trials with tamoxifen, almost all on breast cancer, as of 26 October 2026.

How well did tamoxifen prevent gynecomastia in the trial?

114 men received the antiandrogen bicalutamide for 48 weeks, plus placebo, tamoxifen or anastrozole. Gynecomastia developed in 73 percent on placebo, 10 percent on tamoxifen and 51 percent on anastrozole. Breast pain occurred in 39, 6 and 27 percent.

Why was anastrozole weaker?

Anastrozole lowers the production of estrogen, tamoxifen blocks the effect directly at the receptor in the breast gland. In the trial anastrozole did not significantly reduce gynecomastia. A meta-analysis of 9 trials also found no significant benefit for anastrozole.

What does the meta-analysis show?

Nine randomised trials in men on bicalutamide were included. Tamoxifen lowered the risk of gynecomastia and breast pain by 82 percent (relative risk 0.18). Breast radiotherapy lowered the risk of gynecomastia by 52 percent.

Are there data on gynecomastia of unknown cause?

A breast clinic followed 81 men who received tamoxifen over 10 years. In 90.1 percent the gynecomastia resolved completely. There was no control group, so the evidence is limited.

What happened to the hormones?

Testosterone rose in all groups. With tamoxifen free testosterone stayed the same because the binding protein SHBG rose. Adverse events were not more common with tamoxifen than without (35 versus 37 percent).

Comparações

Como se compara

Relacionados

Produtos relacionados